Meta-Analysis
Copyright ©The Author(s) 2022.
World J Clin Cases. Sep 26, 2022; 10(27): 9703-9713
Published online Sep 26, 2022. doi: 10.12998/wjcc.v10.i27.9703
Figure 1
Figure 1 Preferred reporting items for systematic assessment flow diagram showing the exclusion and inclusion of trials in this systematic evaluation of gemcitabine plus nab-paclitaxel + a targeted drug in metastatic pancreatic cancer. GA: Gemcitabine plus nab-paclitaxel; RCTs: Randomized control trials.